A drug that receives Fast Track designation may benefit from more frequent interactions with the FDA throughout drug development. In addition, the Fast Track program allows for Accelerated Approval ...

The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with ...

a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced that the U.S. Food and Drug ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds, described in a study published January 14 th in the open-access ...

Retinitis pigmentosa (RP) affects approximately 1.5 million people worldwide ... Blood pressure, racial background, a history of cataract surgery and smoking enhance the likelihood of developing dry ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

VG901 employs a novel AAV vector for intravitreal delivery, avoiding retinal damage in treating CNGA1-associated retinitis pigmentosa. ViGeneron's portfolio includes REVeRT and a CRISPR-Cas-based AAV ...